Arcturus Therapeutics to Present at Jefferies London Healthcare Conference
18 Novembro 2024 - 10:00PM
Business Wire
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”,
Nasdaq: ARCT), a commercial messenger RNA medicines company focused
on the development of infectious disease vaccines and opportunities
within liver and respiratory rare diseases, today announced that
the Company will present at Jefferies London Healthcare Conference
in London, on Wednesday, November 20, 2024, at 9:30 am GMT.
A webcast and replay of the presentation will be available on
the Investor Relations/Events section of the Company’s website at:
https://ir.arcturusrx.com/investor-calendar.
About Arcturus
Founded in 2013 and based in San Diego, California, Arcturus
Therapeutics Holdings Inc. (Nasdaq: ARCT) is a commercial mRNA
medicines and vaccines company with enabling technologies: (i)
LUNAR® lipid-mediated delivery, (ii) STARR® mRNA Technology
(sa-mRNA) and (iii) mRNA drug substance along with drug product
manufacturing expertise. Arcturus developed KOSTAIVE®, the first
self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world
to be approved. Arcturus has an ongoing global collaboration for
innovative mRNA vaccines with CSL Seqirus, and a joint venture in
Japan, ARCALIS, focused on the manufacture of mRNA vaccines and
therapeutics. Arcturus' pipeline includes RNA therapeutic
candidates to potentially treat ornithine transcarbamylase (OTC)
deficiency and cystic fibrosis (CF), along with its partnered mRNA
vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus'
versatile RNA therapeutics platforms can be applied toward multiple
types of nucleic acid medicines including messenger RNA, small
interfering RNA, circular RNA, antisense RNA, self-amplifying RNA,
DNA, and gene editing therapeutics. Arcturus' technologies are
covered by its extensive patent portfolio (over 400 patents and
patent applications in the U.S., Europe, Japan, China, and other
countries). For more information, visit www.ArcturusRx.com. In
addition, please connect with us on Twitter and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241118497441/en/
Arcturus Therapeutics Public Relations & Investor
Relations Neda Safarzadeh VP, Head of Investor Relations/PR &
Marketing (858) 900-2682 IR@ArcturusRx.com
Arcturus Therapeutics (NASDAQ:ARCT)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Arcturus Therapeutics (NASDAQ:ARCT)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
